STOCK MARKET BSE NSE

Covaxin being used cautiously in first phase?

The Centre has said that all 1.65 crore doses of the two vaccines have been sent to the states for the first phase of the exercise.

Published: 20th January 2021 09:10 AM  |   Last Updated: 20th January 2021 09:10 AM   |  A+A-

The Centre has procured 55 lakh doses of Covaxin from Bharat Biotech to inoculate healthcare workers.

The Centre has procured 55 lakh doses of Covaxin from Bharat Biotech to inoculate healthcare workers. (File Photo | Vinay Madapu, EPS)

Express News Service

NEW DELHI:  The Centre appears to be taking a wait and watch approach on Covaxin going by its limited use in vaccination of healthcare workers in the first phase of the Covid immunisation drive so far.

As 110 million doses of Serum Institute of India’s Covishield and 55 million doses of Bharat Biotech’s Covaxin were ordered for the first phase of the nationwide drive, the numbers suggest that the two vaccines were to be used in a 2:1 ratio. 

The Centre has said that all 1.65 crore doses of the two vaccines have been sent to the states for the first phase of the exercise.

ALSO READ: People with fever, pregnant and breastfeeding women avoid Covaxin - Bharat Biotech

While Covishield was sent across India, Covaxin was dispatched to 12 states —Andhra Pradesh, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Uttar Pradesh, Telangana and Tamil Nadu.  

But officials in several states this newspaper checked with confirmed that they have each received only 20,000 doses of Covaxin to begin with.

ALSO READ: Centre issues Letter of Comfort to Bharat Biotech for 45 lakh doses of Covaxin

“The supply of the vaccines is being totally controlled by the Centre and even though we have not been given an explanation, it looks like the Health ministry wants to see how the immunisation with this vaccine goes before launching it in a major way,” said a senior Bihar official.

A health bureaucrat in Haryana too confirmed it. “Since Covaxin is being launched in clinical trial mode, the government wants to keep an eye on adverse events and that’s why only a limited number of people will get it during this phase.”



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp